Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03652662 · ClinicalTrials.gov registry record · NA

RESP-FIT: Technology-Enhanced Self-Management in COPD

A NA study, sponsored by Medical University of South Carolina.

Completed
Registry status
NA
Development phase
34
Enrollment target

NCT03652662: Completed NA study, sponsored by Medical University of South Carolina.

NCT03652662 is a NA study that has completed, run by Medical University of South Carolina. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03652662, a NA study, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
NA
Development phase
34 participants
Enrollment target

Study Summary

30 adults, aged 40 and older with mild to moderate COPD, will be recruited for this study. Participants must be willing to continually wear a FitBit activity monitor, have access to a smartphone or Wi-Fi/Data-enabled iPad, and be willing to complete respiratory muscle strength training exercises as well as reports on their smartphone at least 5 times per week for a 6-week period. Participants will be given a bluetooth inhaler device and a training app (RESP-FIT). This application will collect inhaler data and allows patients to self-report their daily symptoms. The goal of this study is to test whether use of the personalized inhaler device with the app strengthens lung function, promotes physical activity, and improves disease symptom self-management in persons with COPD.

Primary Outcome

Feasibility of intervention was measured by the number of participants who adhered to treatment and completed the trial (from baseline to final visit follow-up). Treatment acceptability was measured by the Mobile Application Rating Scale. The Mobile Application Rating Scale asks the participant to report the appropriateness of the app for his/her target audience ranging from little or no (1) to very high level of the acceptability measure (5).

Interventions

  • DEVICE RESP-FIT
  • BEHAVIORAL RESP-FIT Comparator

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2018-01-18
Est. Completion 2020-01-13
Phase NA

What the finished NCT03652662 record still lists

NCT03652662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which RESP-FIT is the first listed.

NCT03652662 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03652662 about?

NCT03652662 is a clinical study titled "RESP-FIT: Technology-Enhanced Self-Management in COPD". 30 adults, aged 40 and older with mild to moderate COPD, will be recruited for this study. Participants must be willing to continually wear a FitBit activity monitor, have access to a smartphone or Wi-Fi/Data-enabled iPad, and be willing to complete respiratory muscle strength training exercises as ...

What is the current status of trial NCT03652662?

This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2018-01-18. Estimated completion is 2020-01-13.

What interventions are being tested in trial NCT03652662?

The interventions under investigation include: RESP-FIT (DEVICE), RESP-FIT Comparator (BEHAVIORAL).

Who is sponsoring clinical trial NCT03652662?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03652662's enrollment target sits among peer trials

34 1570th of 2000 higher than 427 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03652662, the US trial registry maintained by the National Library of Medicine. NCT03652662 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.